Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00917059 · ClinicalTrials.gov registry record · Phase 4
Personalized Indicators for Predicting Response to SSRI Treatment in Major Depression (The PRISE-MD Study)
A Phase 4 study, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 4
- Development phase
- 172
- Enrollment target
NCT00917059 is a Phase 4 study that has completed, run by University of California, Los Angeles. The registered enrollment target is 172 participants.
The verdict
NCT00917059, a Phase 4 study, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 172 participants
- Enrollment target
Study Summary
This study will examine whether measures of brain electrical signals taken after a week of antidepressant medication treatment can predict whether a full treatment regimen will be effective.
Interventions
- DRUG Escitalopram
- DRUG Bupropion XL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 172 participants |
| Start Date | 2009-05 |
| Est. Completion | 2012-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00917059
The ClinicalTrials.gov registry entry for NCT00917059 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 172 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Escitalopram is the first listed.
NCT00917059 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00917059 about?
NCT00917059 is a clinical study titled "Personalized Indicators for Predicting Response to SSRI Treatment in Major Depression (The PRISE-MD Study)". This study will examine whether measures of brain electrical signals taken after a week of antidepressant medication treatment can predict whether a full treatment regimen will be effective.
What is the current status of trial NCT00917059?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 172 participants. The study started on 2009-05. Estimated completion is 2012-05.
What interventions are being tested in trial NCT00917059?
The interventions under investigation include: Escitalopram (DRUG), Bupropion XL (DRUG).
Who is sponsoring clinical trial NCT00917059?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.